Atrium Therapeutics (RNA) Stock Analysis

What Atrium Therapeutics does

Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.

Key metrics

ETFs linked to RNA

Broad-market and Healthcare sector ETFs an investor holding Atrium Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how RNA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Atrium Therapeutics?

Atrium Therapeutics trades under the ticker RNA on NASDAQ.

Which exchange is RNA listed on?

RNA is listed on NASDAQ.

What sector does Atrium Therapeutics operate in?

Atrium Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze RNA in a portfolio?

PortView shows RNA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.